CSIMarket
 
Lumos Pharma Inc   (LUMO)
Other Ticker:  
 
 
Price: $2.7000 $0.05 1.887%
Day's High: $2.8 Week Perf: -11.48 %
Day's Low: $ 2.65 30 Day Perf: -11.48 %
Volume (M): 34 52 Wk High: $ 4.55
Volume (M$): $ 91 52 Wk Avg: $3.27
Open: $2.65 52 Wk Low: $2.51



 Market Capitalization (Millions $) 22
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0

Lumos Pharma Inc
Lumos Pharma Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics for rare diseases. The company primarily targets disorders with serious unmet medical needs and limited treatment options. They aim to bring innovative and effective treatments to patients suffering from these rare diseases. Lumos Pharma's pipeline includes candidates for diseases like Creatine Transporter Deficiency, Pediatric Growth Hormone Deficiency, and Mucopolysaccharidosis Type III. Their mission is to improve patients' quality of life and become a leading player in the rare disease therapeutics market.


   Company Address: 4200 Marathon Blvd #200 Austin 78756 TX
   Company Phone Number: 215-2630   Stock Exchange / Ticker: NASDAQ LUMO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Lumos Pharma Inc

Lumos Pharma Inc Sees Remarkable 61.328% Jump in Revenue During Fourth Quarter of 2023

Lumos Pharma Inc, a pharmaceutical company, recently released its financial results for the fourth quarter of 2023. While the company experienced an increased deficit per share compared to the previous year, it also saw a significant surge in revenue.
During the fourth quarter of 2023, Lumos Pharma Inc reported a deficit per share of $-1.15, which is higher than the $-0.98 per share recorded in the same quarter a year ago. This also represents a slight increase from the $-1.04 per share deficit recorded in the preceding quarter. This indicates that the company's financial performance has worsened in terms of losses per share over the past year.

Lumos Pharma Inc

Lumos Pharma Inc. Reports Alarming Deficit Surge in Fiscal Year 2023

e: October 10, 2023
Lumos Pharma Inc., one of the major players in the pharmaceutical preparations industry, announced its third-quarter financial results for 2023, revealing a deteriorating performance compared to the same period last year. The company recorded a remarkable decline in revenue, plummeting by -98.592% to a meager $0.01 million. The shortfall per share also worsened, expanding to $-1.04 from the prior year's figure.
Contrary to Lumos Pharma's disappointing performance, the Major Pharmaceutical Preparations industry as a whole posted an increase in top-line growth during the third quarter of 2023. However, Lumos Pharma Inc. significantly underperformed its peers, experiencing a sharp decline in revenue by -98.672%, falling from $0.53 million. Earnings per share also dropped from -$1.09 to -$1.04.

Lumos Pharma Inc

An Unusual Execution by Lumos Pharma Inc Shakes Up Q2 2023, Amidst Volatile Stock Performance



Lumos Pharma Inc, a major pharmaceutical preparations company, has recently released its financial results for the second quarter of 2023. While the company experienced a decline in its stock value over the past month, it saw a positive trend over the past five trading days. Furthermore, Lumos Pharma Inc's revenue surged in the second quarter of 2023 compared to the same period the previous year, yet the company reported an increased loss per share. This article aims to interpret these results and discuss their potential implications for Lumos Pharma Inc going forward.
1. Stock Performance:
Lumos Pharma Inc's stock declined by -13.8% during the preceding month. This decline may raise concerns among investors and indicate a loss in market confidence. However, the stock went up by 3.07% over the past five trading days, suggesting a potential recovery in the short term. Investors should closely monitor future stock performance to determine the sustainability of this positive trend.

Lumos Pharma Inc

LUMO Shines Bright with Impressive Q1 Financial Performance

Lumos Pharma Inc is incurring losses at an alarming rate. The company recorded a cumulative net loss of $-31 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on equity (ROE) of -48.26%. This indicates that the company is not generating enough profits to cover its expenses and is a strong bearish signal for investors.
Moreover, the company's total ranking in the industry has deteriorated compared to the fourth quarter of 2022 from 0 to 1365. This shows that Lumos Pharma Inc is not performing as well as other companies in the industry, which is a significant cause of concern.






 

Lumos Pharma Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Lumos Pharma Inc does not provide revenue guidance.

Earnings Outlook
Lumos Pharma Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com